Effects of endurance training on combined goserelin acetate and doxorubicin treatment-induced cardiac dysfunction.
OBJECTIVE
Doxorubicin (DOX) and goserelin acetate (GA), when administered individually, can lead to impaired cardiac function via different mechanisms. Combining GA and DOX (GA + DOX), however, could potentially exacerbate cardiac dysfunction when compared to GA and DOX treatments administered individually. Therefore, the first purpose of this study was to investigate the effects of GA + DOX on cardiac function. Additionally, since exercise training has been shown to protect against GA- and DOX-induced cardiac dysfunction when administered individually, the second purpose of this study was to examine the effects of exercise during GA + DOX on cardiac function.


METHODS
Female rats were randomly assigned to control (CON), GA, DOX, GA + DOX, or exercise training during GA + DOX (EX GA + DOX). Following 56 days, cardiac function was analyzed in vivo using echocardiography and ex vivo using an isolated working heart model.


RESULTS
GA + DOX had significantly lower mitral valve maximal and mean blood flow velocities and aortic valve maximal blood flow velocity than CON (in vivo analysis, P < 0.05), but these differences were not observed between EX GA + DOX and CON. In the isolated working heart, GA + DOX hearts had significantly different left ventricular developed pressures and maximal rates of pressure development and decline than CON (P < 0.05), but these differences were not observed in EX GA + DOX.


CONCLUSIONS
GA + DOX resulted in significantly impaired in vivo and ex vivo cardiac function, but exercise training during GA + DOX was cardioprotective.
School of Sport and Exercise Science, University of Northern Colorado, Greeley, CO 80639, USA.
David S
DS
Hydock
Traci L
TL
Parry
Brock T
BT
Jensen
Chia-Ying
CY
Lien
Carole M
CM
Schneider
Reid
R
Hayward
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001021:Aortic Valve / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004317:Doxorubicin / Q000009:adverse effects*; D004343:Drug Implants; D005260:Female; D017273:Goserelin / Q000009:adverse effects*; D006331:Heart Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D006334:Heart Function Tests; D008943:Mitral Valve / Q000187:drug effects; D009929:Organ Size / Q000187:drug effects; D010805:Physical Conditioning, Animal / Q000502:physiology*; D010807:Physical Endurance / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014463:Ultrasonography; D016277:Ventricular Function, Left / Q000187:drug effects
D000903:Antibiotics, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D004343:Drug Implants; D017273:Goserelin; D004317:Doxorubicin